Skip to main content

Treating HCV Infection: It Doesn't Get Much Better Than This.

Publication ,  Journal Article
Naggie, S
Published in: Top Antivir Med
January 2019

Direct-acting antiviral (DAA) regimens now allow treatment of previously untreated or treated (including prior DAA failures) patients with chronic hepatitis C virus (HCV) infection with 8 or 12 week regimens, largely without the use of ribavirin. Newer next-generation pan-genotypic regimens with activity against resistance-associated substitutions include glecaprevir/pibrentasvir (GLE/PIB), a combination of a nonstructural protein (NS)3 protease inhibitor and an NS5A inhibitor, and sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX), a combination of an NS5B polymerase inhibitor, NS5A inhibitor, and NS3 protease inhibitor. Both regimens have indications in DAA-experienced patients. GLE/PIB is approved for treatment of patients with genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis and for the treatment of patients with genotype 1 infection previously treated with a regimen containing an NS5A inhibitor or an NS3/4A protease inhibitor, but not the combination. SOF/VEL/VOX is approved for retreatment of patients without cirrhosis or with compensated cirrhosis with genotype 1, 2, 3, 4, 5, or 6 infection previously treated with an NS5A inhibitor-containing regimen, or with genotype 1a or 3 previously treated with a SOF-containing regimen without an NS5A inhibitor. This article summarizes an IAS-USA webinar given by Susanna Naggie, MD, MHS, on August 30, 2018.

Duke Scholars

Published In

Top Antivir Med

EISSN

2161-5853

Publication Date

January 2019

Volume

26

Issue

4

Start / End Page

104 / 108

Location

United States

Related Subject Headings

  • United States
  • Treatment Outcome
  • Protease Inhibitors
  • Humans
  • Hepatitis C, Chronic
  • Hepacivirus
  • Genotype
  • Drug Therapy
  • Antiviral Agents
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Naggie, S. (2019). Treating HCV Infection: It Doesn't Get Much Better Than This. Top Antivir Med, 26(4), 104–108.
Naggie, Susanna. “Treating HCV Infection: It Doesn't Get Much Better Than This.Top Antivir Med 26, no. 4 (January 2019): 104–8.
Naggie S. Treating HCV Infection: It Doesn't Get Much Better Than This. Top Antivir Med. 2019 Jan;26(4):104–8.
Naggie, Susanna. “Treating HCV Infection: It Doesn't Get Much Better Than This.Top Antivir Med, vol. 26, no. 4, Jan. 2019, pp. 104–08.
Naggie S. Treating HCV Infection: It Doesn't Get Much Better Than This. Top Antivir Med. 2019 Jan;26(4):104–108.

Published In

Top Antivir Med

EISSN

2161-5853

Publication Date

January 2019

Volume

26

Issue

4

Start / End Page

104 / 108

Location

United States

Related Subject Headings

  • United States
  • Treatment Outcome
  • Protease Inhibitors
  • Humans
  • Hepatitis C, Chronic
  • Hepacivirus
  • Genotype
  • Drug Therapy
  • Antiviral Agents